Patents by Inventor Michael Coyle
Michael Coyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12624369Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: June 28, 2022Date of Patent: May 12, 2026Assignee: Life Edit Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20260125711Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: August 12, 2023Publication date: May 7, 2026Applicant: Life Edit Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Michael Coyle, Gunjan H. Arya, Lisle Mose
-
Publication number: 20260117213Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 14, 2025Publication date: April 30, 2026Applicant: Life Edit Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20260035682Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: October 21, 2025Publication date: February 5, 2026Applicant: Life Edit Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Patent number: 12473539Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: July 23, 2024Date of Patent: November 18, 2025Assignee: Life Edit Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Patent number: 12435325Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: July 23, 2024Date of Patent: October 7, 2025Assignee: Life Edit Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20250283117Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: May 22, 2025Publication date: September 11, 2025Applicant: Life Edit Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Patent number: 12398385Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: July 23, 2024Date of Patent: August 26, 2025Assignee: Life Edit Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Patent number: 12338455Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: February 2, 2024Date of Patent: June 24, 2025Assignee: Life Edit Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Publication number: 20250179529Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: February 13, 2025Publication date: June 5, 2025Applicant: Life Edit Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 12252706Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: April 29, 2024Date of Patent: March 18, 2025Assignee: Life Edit Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20250043315Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 23, 2024Publication date: February 6, 2025Applicant: LifeEDIT Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20240401084Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: February 2, 2024Publication date: December 5, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Publication number: 20240376455Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 23, 2024Publication date: November 14, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20240376456Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 23, 2024Publication date: November 14, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20240294947Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: April 29, 2024Publication date: September 5, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11981916Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 1, 2022Date of Patent: May 14, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11926843Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 17, 2021Date of Patent: March 12, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Publication number: 20240026384Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: August 10, 2023Publication date: January 25, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11859181Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: August 31, 2022Date of Patent: January 2, 2024Assignee: LIFEEDIT THERAPEUTICS, INC.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich